지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학위논문
- 저자정보
- 지도교수
- 염경호
- 발행연도
- 2018
- 저작권
- 충북대학교 논문은 저작권에 의해 보호받습니다.
이용수4
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
The membrane emulsification (ME) is a technology to produce uniform emulsions with narrow size distribution by using the well-defined porous membranes such as the SPG (Shirasu porous glass) membrane.
In this work, the preparation of polycaprolactone (PCL) microcapsules containing BSA (bovine serum albumin) model drug by the premix membrane emulsification method was studied. After the making of W1/O single emulsions by sonication method, then W1/O/W2 multiple emulsions are formed by premix-ME method. The inner aqueous phase (W1) with BSA is added to the oil phase with PCL and emulsifier (Span 80) and then sonicated to form W1/O single emulsions. The W1/O single emulsions are permeated through the SPG membrane (pore size 2.5 μm) into a continuous phase (W2) containing poly(vinyl alcohol) in order to form W1/O/W2 multiple emulsions. Finally, the PCL microcapsules impregnated with BSA model drug are obtained by solvent evaporating from the W1/O/W2 multiple emulsions.
The effects of various parameters such as the ratio of disperse/continuous phase (D/C ratio), the concentration of PCL, emulsifier and model drug and the transmembrane pressure on the size and distribution of PCL microcapsules are investigated. The uniform PCL microcapsules with about 5～6 μm of mean size and 26% of BSA loading are obtained by the premix membrane emulsification. Also, the release properties of BSA model drug from the PCL microcapsules are tested.
In this work, the preparation of polycaprolactone (PCL) microcapsules containing BSA (bovine serum albumin) model drug by the premix membrane emulsification method was studied. After the making of W1/O single emulsions by sonication method, then W1/O/W2 multiple emulsions are formed by premix-ME method. The inner aqueous phase (W1) with BSA is added to the oil phase with PCL and emulsifier (Span 80) and then sonicated to form W1/O single emulsions. The W1/O single emulsions are permeated through the SPG membrane (pore size 2.5 μm) into a continuous phase (W2) containing poly(vinyl alcohol) in order to form W1/O/W2 multiple emulsions. Finally, the PCL microcapsules impregnated with BSA model drug are obtained by solvent evaporating from the W1/O/W2 multiple emulsions.
The effects of various parameters such as the ratio of disperse/continuous phase (D/C ratio), the concentration of PCL, emulsifier and model drug and the transmembrane pressure on the size and distribution of PCL microcapsules are investigated. The uniform PCL microcapsules with about 5～6 μm of mean size and 26% of BSA loading are obtained by the premix membrane emulsification. Also, the release properties of BSA model drug from the PCL microcapsules are tested.
목차
Ⅰ. 서 론 1Ⅱ. 연구배경 6Ⅱ-1. 막유화의 원리 6Ⅱ-2. SPG 막 9Ⅱ-3. 막유화 공정 13Ⅲ. 실 험 19Ⅲ-1. 실험재료 및 장치 19Ⅲ-2. 실험방법 22Ⅲ-2-1. PCL 마이크로캡슐의 제조 22Ⅲ-2-2. PCL 마이크로캡슐의 크기 및 분포 측정 26Ⅲ-2-3. 모델 약물의 함침량과 방출 특성 평가 26Ⅳ. 결과 및 고찰 28Ⅳ-1. PCL 마이크로캡슐의 제조 28Ⅳ-1-1. D/C 비율의 영향 28Ⅳ-1-2. 유화제 농도의 영향 29Ⅳ-1-3. PCL 농도의 영향 33Ⅳ-1-4. PCL 분자량의 영향 38Ⅳ-1-5. BSA 농도의 영향 41Ⅳ-1-6. 막간 압력의 영향 46Ⅳ-2. 모델 약물의 함침량과 방출 특성 49Ⅳ-2-1. BSA 함침량 49Ⅳ-2-2. 약물방출 특성 52Ⅴ. 결 론 54참고문헌 55
최근 본 자료
댓글(0)
0